2022 International Virtual Conference
on Human Retrovirology: HTLV 2022
8 - 11 May 2022

Dr Genoveffa Franchini

Dr. Genoveffa Franchini is a hematologist and renowned retrovirologist who has pioneered research on oncogenes and human retroviruses (HTLVs and HIVs). She has made numerous achievements in virology and translational approaches to prevent human diseases caused by retroviruses. Her work has furthered the understanding of HIV and HTLV-1 pathogenesis, leading to the identification and characterization of new viral genes for HIV and HTLV-1 and their functions. Her accomplishments in HIV vaccine development include the pre-clinical that led to the first vaccine trial in 16,000 volunteers in Thailand, that has demonstrated significant, though limited, protection against HIV acquisition. Her basic work in immunological mechanisms of protection furthered the understanding of the efficacy of the currently available smallpox vaccine in primates. She also has pioneered strategies to down-modulate regulators of immune response in HIV-1-infected individuals, using the macaque model of SIV infection.

Professor Graham Taylor

Head of Section of Virology, Department of Infectious Disease, Imperial College London. 

Qualified MB ChB, University of Birmingham, England 1981. Trained in General Internal Medicine in England and Old South Wales before appointment as Chief Medical Officer (Medicine), Solomon Islands 1988. Joined St. Mary’s Hospital Medical School 1992, co-founded a HTLV-1 research clinic which in 2004 evolved into the National Centre for Human Retrovirology, a centrally funded, multi-site, national HTLV clinical service. Leads a retroviruses translational research group focusing on diagnostics and therapy. 

Past Secretary 2001 – 2005 and President 2005 – 2009 of the International Retrovirology Association.  Co-founder and honorary secretary of the HTLV European Research Network (1993 – present). 

Copyright 2021 by ASHM Conference & Events Division | info@htlvconference2022.com | +61 2 8204 0770